Literature DB >> 1612734

In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin.

A S Hawes1, C S Rock, C V Keogh, S F Lowry, S E Calvano.   

Abstract

The endogenous adrenocortical response to sepsis is critical for host survival. The in vivo interactions among the endogenous glucocorticoid response, the induction of cytokines, and host survival during endotoxemia were explored in this study by use of the glucocorticoid receptor antagonist RU 486. Male Lewis rats underwent sterile insertion of a right jugular venous catheter. After a 72-h recovery period, animals received a 50% lethal dose of Escherichia coli endotoxin (2.5 mg/kg) via the catheter after pretreatment for 30 min prior to lipopolysaccharide (LPS) treatment with (i) vehicle alone intravenously (i.v.) (-corticosterone [-Cort]/-RU 486/+LPS) (n = 10), (ii) the antiglucocorticoid RU 486 (10 mg/kg) i.v. (-Cort/+RU 486/+LPS) (n = 11), or (iii) RU 486 (10 mg/kg) i.v. in animals that had undergone subcutaneous implantation of a corticosterone pellet at the time of catheter insertion (+Cort/+RU 486/+LPS) (n = 10). Except in animals receiving corticosterone pretreatment, baseline plasma corticosterone levels were low in all groups. Plasma corticosterone levels increased significantly (P less than 0.001) above the baseline following LPS administration. Animals in the -Cort/+RU 486/+LPS-treated group exhibited significantly increased mortality (P less than 0.001), with only 9% of the animals surviving at 72 h, as well as significantly increased plasma interleukin-6 levels, compared with animals receiving the vehicle alone (-Cort/-RU 486/+LPS), which showed 50% mortality. Pretreatment with corticosterone and RU 486 (+Cort/+RU 486/+LPS) significantly (P less than 0.001) reversed the mortality observed with RU 486 pretreatment alone (-Cort/+RU 486/+LPS), with 70% of the animals surviving at 72 h, and significantly attenuated the peak plasma tumor necrosis factor and interleukin-6 responses to LPS, compared with those in the animals treated with vehicle alone. These data demonstrate that the blockade of glucocorticoid binding by RU 486 increases LPS-induced mortality. The reversal of this effect by the induction of hypercorticosteronemia prior to RU 486 and LPS exposure (+Cort/+RU 486/+LPS) improves survival and is further associated with significant attenuation of cytokine production. Therefore, these data suggest that the protective effect of the endogenous glucocorticoid response to acute endotoxemia may result from the down-regulation of a potentially lethal cytokine response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1612734      PMCID: PMC257215          DOI: 10.1128/iai.60.7.2641-2647.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates.

Authors:  E Fischer; M A Marano; A E Barber; A Hudson; K Lee; C S Rock; A S Hawes; R C Thompson; T J Hayes; T D Anderson
Journal:  Am J Physiol       Date:  1991-08

2.  Pathophysiologic glucocorticoid levels and survival of translocating bacteria.

Authors:  W G Jones; A E Barber; S Kapur; A J Hawes; T J Fahey; J P Minei; G T Shires; S E Calvano; G T Shires
Journal:  Arch Surg       Date:  1991-01

3.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

4.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock.

Authors:  K Ohlsson; P Björk; M Bergenfeldt; R Hageman; R C Thompson
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

5.  Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog.

Authors:  J C Preiser; D Schmartz; P Van der Linden; J Content; P Vanden Bussche; W Buurman; W Sebald; E Dupont; M R Pinsky; J L Vincent
Journal:  Cytokine       Date:  1991-01       Impact factor: 3.861

6.  Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.

Authors:  J C Mathison; E Wolfson; R J Ulevitch
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

7.  Increased plasma levels of interleukin-6 in sepsis.

Authors:  C E Hack; E R De Groot; R J Felt-Bersma; J H Nuijens; R J Strack Van Schijndel; A J Eerenberg-Belmer; L G Thijs; L A Aarden
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

8.  EFFECTS OF BACTERIAL ENDOTOXINS ON METABOLISM. VII. ENZYME INDUCTION AND CORTISONE PROTECTION.

Authors:  L J BERRY; D S SMYTHE
Journal:  J Exp Med       Date:  1964-11-01       Impact factor: 14.307

9.  Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor.

Authors:  R Bertini; M Bianchi; P Ghezzi
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

10.  Hydrazine sulfate protects D-galactosamine-sensitized mice against endotoxin and tumor necrosis factor/cachectin lethality: evidence of a role for the pituitary.

Authors:  R Silverstein; B R Turley; C A Christoffersen; D C Johnson; D C Morrison
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

View more
  15 in total

1.  Glucocorticoids exert opposing effects on macrophage function dependent on their concentration.

Authors:  Hee-Young Lim; Nora Müller; Marco J Herold; Jens van den Brandt; Holger M Reichardt
Journal:  Immunology       Date:  2007-04-23       Impact factor: 7.397

2.  NETWORKS, BIOLOGY AND SYSTEMS ENGINEERING: A CASE STUDY IN INFLAMMATION.

Authors:  P T Foteinou; E Yang; I P Androulakis
Journal:  Comput Chem Eng       Date:  2009-12-10       Impact factor: 3.845

3.  "Anatomy of an Illness": control from a caregiver's perspective.

Authors:  Mark L Laudenslager
Journal:  Brain Behav Immun       Date:  2013-09-06       Impact factor: 7.217

4.  Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram.

Authors:  E R Pettipher; J M Labasi; E D Salter; E J Stam; J B Cheng; R J Griffiths
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

5.  Pharmacokinetic/pharmacodynamic modeling of methylprednisolone effects on iNOS mRNA expression and nitric oxide during LPS-induced inflammation in rats.

Authors:  Siddharth Sukumaran; Eve-Irene Lepist; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Pharm Res       Date:  2012-03-16       Impact factor: 4.200

6.  Glucocorticoids and TNFalpha interact cooperatively to mediate sepsis-induced leucine resistance in skeletal muscle.

Authors:  Charles H Lang; Robert A Frost
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

7.  Inhibition of some aspects of acute inflammation of guinea-pig lung by intraperitoneal dexamethasone and mifepristone: demonstration of agonist activity of mifepristone in the guinea-pig.

Authors:  C J Whelan; S C Hughes; G P Wren
Journal:  Inflamm Res       Date:  1995-03       Impact factor: 4.575

8.  Serum corticosterone, interleukin-1 and tumour necrosis factor in rat experimental endotoxaemia: comparison between Lewis and Wistar strains.

Authors:  M Perretti; G S Duncan; R J Flower; S H Peers
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

9.  GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology.

Authors:  Haiyun Liu; Lei Huang; Jillian Bradley; Kebin Liu; Kankana Bardhan; David Ron; Andrew L Mellor; David H Munn; Tracy L McGaha
Journal:  Mol Cell Biol       Date:  2013-11-18       Impact factor: 4.272

10.  In silico simulation of corticosteroids effect on an NFkB- dependent physicochemical model of systemic inflammation.

Authors:  Panagiota T Foteinou; Steve E Calvano; Stephen F Lowry; Ioannis P Androulakis
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.